| Not Yet Recruiting | Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease Non Small Cell Lung Cancer Metastatic, Interstitial Lung Disease (ILD) | Phase 2 | 2026-05-15 |
| Recruiting | Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropa Neuroendocrine Carcinoma | Phase 3 | 2026-02-06 |
| Not Yet Recruiting | Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With P Pleural Mesotheliomas | Phase 2 | 2026-02-01 |
| Recruiting | Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previ Advanced Non Small Cell Lung Cancer, MET Exon 14 Mutation | Phase 3 | 2025-12-09 |
| Recruiting | Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients Stage III NSCLC | Phase 2 | 2025-11-07 |
| Recruiting | Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned Af Pleural Mesotheliomas | Phase 2 | 2025-06-30 |
| Recruiting | A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib i Non Small Cell Lung Cancer, EGFR Activating Mutation, EGFR DEL19 | N/A | 2024-01-22 |
| Active Not Recruiting | Durvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease Small-sell Lung Cance Small Cell Lung Cancer Extensive Stage | Phase 2 | 2023-11-17 |
| Active Not Recruiting | Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunot Non Small Cell Lung Cancer | Phase 2 | 2023-04-26 |
| Active Not Recruiting | Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Non Small Cell Lung Cancer, ALK Gene Mutation | Phase 2 | 2022-05-18 |
| Recruiting | De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control Metastatic NSCLC | Phase 2 / Phase 3 | 2022-05-02 |
| Completed | RW Effectiveness of Lurbinectedin in Extensive Stage SCLC Small-cell Lung Cancer | — | 2022-04-01 |
| Unknown | RW Efficacy of Sotorasib in KRAS G12C-mutated Metastatic NSCLC Nsclc, KRAS P.G12C | — | 2022-03-01 |
| Completed | RW Effectiveness of Capmatinib in Advanced MET-dysregulated NSCLC Included in the French Compassionate Use Pro MET Alterations, Non Small Cell Lung Cancer, METex14 Mutations | — | 2021-11-29 |
| Active Not Recruiting | Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS) Non Small Cell Lung Cancer Metastatic | Phase 2 | 2021-03-19 |
| Completed | BRAF V600-mutated Lung Carcinoma Treated With the Combination of Dabrafenib-trametinib: a Retrospective Evalua Non Small Cell Lung Cancer, BRAF V600 Mutation | — | 2021-03-08 |
| Completed | Atezolizumab Combined With Chemotherapy in Extensive Stage SCLC Small Cell Lung Cancer | — | 2021-02-02 |
| Active Not Recruiting | ENCOrafenib With Binimetinib in bRAF NSCLC Non Small Cell Lung Cancer, BRAF V600E | Phase 2 | 2021-01-19 |
| Completed | Immunotherapy in Patient With Poor General Condition Non-small Cell Lung Cancer Stage IV | Phase 2 | 2020-10-14 |
| Completed | Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-po Non Small Cell Lung Cancer Metastatic | Phase 2 | 2020-08-05 |
| Completed | Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation Non Small Cell Lung Cancer Metastatic, Leptomeningeal Metastasis, Brain Metastases | Phase 2 | 2020-07-16 |
| Active Not Recruiting | Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Non Small Cell Lung Cancer Metastatic | Phase 3 | 2019-07-23 |
| Completed | Her2-positive Lung Cancer Treated With Dedicated Drug Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer Stage III, HER2 Gene Mutation | Phase 2 | 2019-05-17 |
| Completed | Efficacy of Treatment Sequences in Patients With Non-small Cell Lung Cancer Receiving Lorlatinib Non-small Cell Lung Cancer Metastatic, ALK Gene Rearrangement Positive, ROS-1 Gene Rearrangement Positive | — | 2019-02-01 |
| Completed | Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Diff Neuroendocrine Carcinoma | Phase 2 | 2019-01-02 |
| Completed | Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr Non-Small Cell Lung Cancer Metastatic | Phase 3 | 2018-05-02 |
| Completed | Immunotherapy by Nivolumab for HIV+ Patients Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer Stage IIIB, HIV/AIDS | Phase 2 | 2017-10-19 |
| Completed | Immunotherapy as Second-line in Patient With Small Cell Lung Cancer Small Cell Lung Cancer, Small Cell Lung Cancer Limited Stage, Small Cell Lung Cancer Extensive Stage | Phase 2 | 2017-03-13 |
| Terminated | Immune Neoadjuvant Therapy Study of Durvalumab in Early Stage Non-small Cell Lung Cancer Carcinoma, Non-Small-Cell Lung | Phase 2 | 2017-01-12 |
| Completed | Cohort of Patients With NSCLC Treated With Nivolumab Under the ATU Program Non-small Cell Lung Cancer, Nivolumab, Long-term Adverse Effects | — | 2016-09-01 |
| Completed | Combination of Cetuximab With Afatinib for Patient With EGFR Mutated Lung Cancer Non Small Cell Lung Cancer | Phase 2 | 2016-05-01 |
| Completed | Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Pati Mesothelioma | Phase 2 | 2016-03-24 |
| Completed | Description of Clinical Anatomical Features and Long Term Follow-up for Patients With ALK Rearrangements Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase Gene Mutation | — | 2014-05-01 |
| Completed | Maintenance After Induction Chemotherapy in Elderly Patients With Advanced Non-small Cell Lung Cancer Non Small Cell Lung Cancer (Squamous or Non Squamous) | Phase 3 | 2013-05-16 |
| Completed | Paclitaxel-bevacizumab in Advanced Lung Cancer Non-squamous Non-small Cell Lung Cancer | Phase 3 | 2013-05-01 |
| Completed | Re-introduction of Pemetrexed and Cisplatin With Prolonged Angiogenic Blocking by Bevacizumab in Advanced Lung Non-small Cell Lung Cancer Metastatic, Nonsquamous Nonsmall Cell Neoplasm of Lung | Phase 2 | 2012-12-01 |
| Completed | Strategies for Maintenance Therapies in Advanced Non Small Cell Lung Cancer Advanced Non Small Cell Lung Cancer | Phase 3 | 2012-07-01 |
| Completed | Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFR Stage IV Lung Cancer | Phase 2 | 2012-05-15 |
| Completed | French National Observatory of the Patients With Non-small Cell Lung (NSCLC) and Molecular Testings Carcinoma, Non-Small-Cell Lung, ALK Gene Mutation, KRAS Gene Mutation | — | 2012-04-01 |
| Unknown | French National Observatory of Patients With Thymic Epithelial Tumor Thymic Epithelial Tumor | — | 2012-01-01 |
| Completed | French Biological Observatory on Lung Cancer in Never Smokers Lung Cancer | — | 2011-11-01 |
| Completed | Chemotherapy for Lung Cancer in HIV-positive Patients Non-small Cell Lung Cancer, Hiv-positive | Phase 2 | 2011-05-01 |
| Completed | Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC) Stage III Non-small Cell Lung Cancer | Phase 2 | 2010-03-01 |
| Completed | Bevacizumab in Extensive Small Cell Lung Cancer Small Cell Lung Cancer | Phase 2 / Phase 3 | 2009-09-01 |
| Completed | TAilored Post-Surgical Therapy in Early Stage NSCLC Carcinoma, Non-Small-Cell Lung | Phase 2 / Phase 3 | 2009-04-01 |
| Completed | Adjuvant Pazopanib in Stage I NSCLC Carcinoma, Non-Small-Cell Lung | Phase 2 / Phase 3 | 2008-11-01 |
| Completed | Mesothelioma Avastin Plus Pemetrexed-cisplatin Study Mesothelioma | Phase 2 / Phase 3 | 2008-02-01 |
| Terminated | NSCLC Relapse Therapy After Surgery and Peri-operative Chemotherapy Carcinoma, Non-Small-Cell Lung | Phase 3 | 2007-09-01 |
| Completed | Therapeutic Strategy in Advanced Bronchioloalveolar Carcinoma Adenocarcinoma, Bronchiolo-Alveolar | Phase 2 | 2006-09-01 |
| Completed | Chemotherapy of Elderly Patients With Non-Small-Cell Lung Cancer (NSCLC) NSCLC | Phase 3 | 2006-03-01 |
| Completed | Treatment of Lung Adenocarcinoma With Bronchioloalveolar Feature Pneumonic-type Adenocarcinoma (P-ADC), Lung Adenocarcinoma With Bronchiolo-alveolar Feature | Phase 2 | 2005-04-01 |
| Completed | Post-Surgical Non-Small Cell Lung Cancer (NSCLC) Follow-up Non-Small-Cell Lung Carcinoma | N/A | 2005-01-01 |
| Completed | Randomized Phase 2 Study of 3 Therapeutic Modalities in PS 2/3 Patients With NSCLC Stage IIIB/IV Carcinoma, Non-Small-Cell Lung | Phase 2 | 2004-11-01 |
| Completed | A FRENCH SURVEY OF THE DIAGNOSTIC AND THERAPEUTIC MANAGEMENT OF ELDERLY PEOPLE WITH HISTOLOGICALLY/CYTOLOGICAL ELDERLY PEOPLE, Non-small Cell Lung Cancer | — | 2002-09-01 |
| Completed | Chemoradiotherapy of NSCLC Stage IIIB NSCLC Stage IIIB, Concomitant Radiochemotherapy | Phase 2 | 2002-03-01 |
| Completed | Stage I/II NSCLC Perioperative Chemotherapy Non-small Cell Lung Cancer Stage I and II, Peri-operative Chemotherapy | Phase 3 | 2001-05-01 |